𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma : A meta–analysis

✍ Scribed by Maurice P.A. Zeegers; Annemarie Jellema; Harry Ostrer

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
126 KB
Volume
97
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

Although narrative reviews have concluded that there is strong support for familial clustering of prostate carcinoma, the association has never systematically been quantified in reviews. The purpose of this meta–analysis was to summarize and quantify the recurrence risk ratio with emphasis on the degree of relation, the specific relationship of the family member, the number of affected family members, and the age at diagnosis.

METHODS

Publications were identified through computerized database searches for epidemiologic studies published up to December 2002. In addition, references cited in original and review papers were examined. Three blinded reviewers extracted both qualitative and quantitative information from each paper. Using random effects meta–regression analyses, the authors calculated summary recurrence risk ratios (Sλ). The reviewers also evaluated changes in Sλ according to differences in study methodology.

RESULTS

Thirty–three epidemiologic studies were included in the current review. Sλ was 2.53 (95% confidence interval, 2.24–2.85) for first–degree family members. Sλ appeared to be greater for men with an affected brother than for men with an affected father. Sλ for men who had second–degree relatives with prostate carcinoma was only slightly elevated. The nature of the familial clustering is such that Sλ increases with decreasing age of the patient and family members, with increasing genetic relatedness of the affected relative, and with increasing number of individuals affected within a family.

CONCLUSIONS

The studies that were reviewed consistently demonstrate that family history is a significant risk factor for development of prostate carcinoma. Cancer 2003;97:1894–903. © 2003 American Cancer Society.

DOI 10.1002/cncr.11262

📜 SIMILAR VOLUMES

Relative risk of prostate cancer for men
Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis
✍ Deborah Watkins Bruner; Dirk Moore; Alicia Parlanti; Joanne Dorgan; Paul Engstro 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 273 KB 👁 1 views

## Abstract An increased risk of prostate cancer associated with a family history of prostate cancer has been documented in multiple published reports. Risk has been shown to vary by degree of relationship and age of onset of disease in the affected relative. Several studies, using various designs,

Meta-analysis for combining relative ris
Meta-analysis for combining relative risks of alcohol consumption and prostate cancer
✍ Dennis, Leslie K. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

## BACKGROUND. Prostate cancer has become the most common cancer among men in the United States, but little is known about factors associated with prostate cancer incidence. METHODS. A meta-analysis of studies published prior to July 1998 was conducted to pool relative risk (RR) estimates from the

Systematic review and meta-analysis of m
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
✍ David J. Samson; Jerome Seidenfeld; Brian Schmitt; Vic Hasselblad; Peter C. Albe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## BACKGROUND The current systematic review and meta‐analysis compared monotherapy and combined androgen blockade in the treatment of men with advanced prostate carcinoma. Outcomes of interest included overall, cancer specific, and progression‐free survival; time to treatment failure;

Thromboembolic events with estramustine
Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma : Results of a meta-analysis
✍ Gregory M. Lubiniecki; Jesse A. Berlin; Rachel B. Weinstein; David J. Vaughn 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract ## BACKGROUND Combinations of cytotoxic chemotherapy with estramustine phosphate (EMP), a nornitrogen mustard‐estrogen conjugate, are used to treat patients with hormone‐refractory prostate carcinoma (HRPC). However, thromboembolic events (TE), including deep venous thrombosis (DVT), p